Abb (H2-Ab1) - Model 4026

Constitutive Knockout

Abb (H2-Ab1) 4026 Constitutive Knockout Mouse Model
EZcohort® Models
The easiest way to acquire and breed cryopreserved GEMs
LEARN MORE
This model is available for immediate cryorecovery.

B6.SJL Background

  • Model #
  • Genotype
  • Nomenclature
  • 4026
    B6.SJL(129)-Ptprca H2-Ab1tm1Gru
  • Contains a disruption of the H2-Ab1 gene
  • Expresses no A or E MHC class II molecules and therefore lacks most CD4+ T cells
  • Useful in transplantation, gene therapy and immunological disease research
  • The Ptprca marker on hematopoietic cells of this congenic strain allows for their identification in immunological adoptive transfer experiments

Genetic Background:

C57BL/6-Ptprc a Background

Origin:

The Abb mouse was developed in the laboratory of Michael J. Grusby et al. of the Harvard School of Public Health. The model was created by targeting the H2-Ab1 gene in ES-D3 cells and injecting the targeted ES cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to C57BL/6 for 7 generations (N7), then backcrossed four generations (N4) to B6.SJL- Ptprca. NIAID received stock in 1994, and Taconic received stock in 1995 for the NIAID Transgenic Mouse Repository. The mice were then derived via backcross to B6.SJL-Ptprca. The mice were backcrossed once more to B6.SJL-Ptprca (N5), then intercrossed to homozygosity for both Abb and Ptprca. The mice were derived by embryo transfer again in 1997 (N6). The line was maintained by incrossing homozygous mice.


Genetics:

Wild type for Nnt mutation, carries Pde6brd1 mutation


Color:

Black

Species:

Mouse

Initial Publication:

Grusby MJ, Johnson RS, Papaioannou VE, Glimcher LH. (1991) Depletion of CD4+ T-Cells in Major Histocompatibility Complex Class II - Deficient Mice. Science, 253(5026):1417-1420.



To purchase this EZcohort model, sign the terms of sale (choose from the list below) and email it directly to info@taconic.com with a purchase order for the purchase price:

This model is sold under terms which grant perpetual use rights.